Reply: Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

Abstract

We have read with interest the article by Piaserico et al. concerning the use of tumour necrosis factor-alpha (TNF-alpha) blocking agent adalimumab in psoriatic patients with concomitant hepatitis B virus (HBV) or hepatitis C virus (HCV). The authors describe 17 psoriatic patients affected by chronic HBV infection and 20 affected by chronic HCV who were successfully treated with adalimumab with no evidence of HBV or HCV reactivation in a mean follow-up period of 27 and 40 months, respectively.

We have previously described our successful experience of treatment with anti-TNF-alpha therapy in 17 psoriatic patients (11 with past HBV infection, 5 with chronic HCV infection and one affected by both HBV and HCV) without the use of lamivudine or adenofovir, and can now report on long-term follow-up data (mean follow-up period of 60 months).

This article is protected by copyright. All rights reserved.

http://ift.tt/2p8HrxB